|
2019 Journal Article The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancerTurner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Hughes, Brett G. M., McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Paviour, Alana, Skerman, Helen, Batstone, Martin and Mackenzie, Lisa (2019). The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. Supportive Care in Cancer, 27 (12), 4627-4637. doi: 10.1007/s00520-019-04748-7 |
|
2019 Conference Publication Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN)Ahern, Elizabeth Stephanie, Cubitt, Annette, Ballard, Emma, Teng, Michele W.L., Dougall, William C., Smyth, Mark J. and Hughes, Brett Gordon Maxwell (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA United States, 28 February — 2 March 2019. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2019.37.8_suppl.tps129 |
|
2019 Journal Article Patterns of care for stage III non–small cell lung cancer in AustraliaParente, Phillip, Chan, Bryan A., Hughes, Brett G. M., Jasas, Kevin, Joshi, Rohit, Kao, Steven, Hegi-Johnson, Fiona, Hui, Rina, McLaughlin-Barrett, Sara, Nordman, Ina and Stone, Emily (2019). Patterns of care for stage III non–small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 15 (3), 93-100. doi: 10.1111/ajco.13140 |
|
2019 Conference Publication Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET stagingSenko, Clare, Moore, Julie, Hay, Karen, Lwin, Zarnie, Pratt, Gary, Fong, Kwun and Hughes, Brett Gordon Maxwell (2019). Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. |
|
2019 Conference Publication Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Baste, Neus, Neupane, Prakash C., Bratland, Ase, Fuereder, Thorsten, Hughes, Brett Gordon Maxwell, Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Zhang, Yayan, Jin, Fan, Gumuscu, Burak and Burtness, Barbara (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6000 |
|
2019 Conference Publication KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC)Grob, Jean Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica Ruth, Grange, Florent, Meyer, Nicolas, Piulats, Josep M., Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett Gordon Maxwell (2019). KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.TPS9598 |
|
2019 Conference Publication Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-upGuminski, Alexander David, Lim, Annette May Ling, Khushalani, Nikhil I., Schmults, Chrysalyne D., Hernandez-Aya, Leonel Fernando, Modi, Badri, Dunn, Lara, Hughes, Brett Gordon Maxwell, Chang, Anne Lynn S., Hauschild, Axel, Migden, Michael Robert, Gutzmer, Ralf, Alam, Murad, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2019). Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.9526 |
|
2019 Conference Publication Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC)Wirth, Lori J., Leboulleux, Sophie, Kiyota, Naomi, Tahara, Makoto, Muro, Kei, Ahn, Myung-Ju, Ando, Yuichi, Taylor, Matthew H., Takahashi, Shunji, Kim, Sung-Bae, Misir, Soamnauth, Dutcus, Corina E., Xie, Ran, Joshi, Prashant Ramesh, Hughes, Brett Gordon Maxwell, Aller, Javier, Krzyzanowska, Monika K. and Capdevila, Jaume (2019). Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6081 |
|
2018 Journal Article Pembrolizumab as palliative immunotherapy in malignant pleural mesotheliomaMetaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia A., Klingbiel, Dirk, Kao, Steven, Schmid, Sabine, Nowak, Anna K., Gautschi, Oliver, Bartnick, Tammo, Hughes, Brett G., Bouchaab, Hasna, Rothschild, Sacha I., Pavlakis, Nick, Wolleb, Sibylle, Petrausch, Ulf, O'Byrne, Kenneth, Froesch, Patrizia, Löffler-Baumann, Melanie, Pratsch-Peter, Susanne, Russell, Prudence, Mingrone, Walter, Savic, Spasenija, Thapa, Bibhusal, Früh, Martin, Pless, Miklos, von Moos, Roger and John, Thomas (2018). Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13 (11), 1784-1791. doi: 10.1016/j.jtho.2018.08.007 |
|
2018 Conference Publication Thromboembolism in ROS1 Rearranged Non-Small Cell Lung CancerItchins, M., Alexander, M., John, T., Kao, S., Hughes, B., Hayes, S., Howel, V., Harvie, R., Clarke, S., Millward, M. and Pavlakis, N. (2018). Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jtho.2018.08.1104 |
|
2018 Journal Article Identifying barriers to physical activity in patients with lung cancer: an Australian pilot studyTran, Q., Schimdt, A., Lwin, Z. and Hughes, B. G. M. (2018). Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study. Annals of Oncology, 29, viii756. doi: 10.1093/annonc/mdy424.088 |
|
2018 Conference Publication KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., De Castro, G., Psyrri, A., Rotllan, N. Baste, Neupane, P. C., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. Wan, Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., De Castro, G., Psyrri, A., Baste Rotllan, N., Neupane, P. C., Bratland,, Fuereder, T., Hughes, B. G.M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.045 |
|
2018 Journal Article PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaMigden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., Li, J., Mathias, M., Booth, J., Mohan, K., Stankevich, E., Babiker, H. M., Brana, I., Gil-Martin, M., Homsi, J. ... Fury, M. G. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of Medicine, 379 (4), 341-351. doi: 10.1056/NEJMoa1805131 |
|
2018 Journal Article Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patternsMoroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Burns, Clare L., Yeo, Shu Qi, Pelecanos, Anita, Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Supportive Care in Cancer, 27 (2), 1-9. doi: 10.1007/s00520-018-4352-5 |
|
2018 Journal Article CXCR4 and PD-1 expression in head and neck cancer with perineural spreadBarnett, Catherine M., Sommerville, Ryan S., Lin, Charles, Ratnayake, Gishan, Hughes, Brett and Taheri, Touraj (2018). CXCR4 and PD-1 expression in head and neck cancer with perineural spread. Journal of Neurological Surgery, Part B: Skull Base, 80 (01), 018-022. doi: 10.1055/s-0038-1660846 |
|
2018 Journal Article Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patternsMoroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Pelecanos, Anita, Burns, Clare L., Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns. Head & Neck, 40 (9), 1955-1966. doi: 10.1002/hed.25182 |
|
2018 Journal Article Osimertinib in Untreated <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung CancerSoria, J. -C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. -C., Gray, J. E., Lee, S. -M., Hodge, R., Marotti, M., Rukazenkov, Y., Ramalingam, S. S., Boyer, Michael, Lee, Chee, Hughes, Brett, O'Byrne, Kenneth, Briggs, Peter ... Nguyen, Nhung (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378 (2), 113-125. doi: 10.1056/NEJMoa1713137 |
|
2018 Conference Publication Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLCSocinski, M. A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R. A., Palmero, R., Kozuki, T., Migliorino, M. R., Koynov, K. D., Berard, H., Hughes, B. G. M., Yu, W., Graupner, V., Sun, S. W., Kowanetz, M., Hoang, T., Lin, W. and Jotte, R. M. (2018). Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC. 43rd ESMO Congress, Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy424.077 |
|
2018 Conference Publication BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLCKulkarni, S., Laurie, S., Goss, G., Perrone, F., Hughes, B., Pavlakis, N., Stockler, M., Blais, A., Zibdawi, L., Vera-Badillo, F. and Leighl, N. (2018). BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLC. IASLC 19th World Conference on Lung Cancer, Toronto, Canada, 23-26 September 2018. New York, NY USA: Elsevier. doi: 10.1016/j.jtho.2018.08.608 |
